



BD FACS Permeabilizing Solution 2

Catalog No. 340973

500 Tests

APPLICATION

Intracellular staining of antigens, cytokines and other proteins¹⁻¹⁰

DESCRIPTION

BD FACS™ Permeabilizing Solution 2 (10X) is a premixed concentrate formulated specifically for use in flow cytometry. It is intended for the permeabilization of lymphocyte membranes prior to intracellular immunofluorescence staining with monoclonal antibodies. This formulation is designed for antigen-specific activation applications. BD FACS Permeabilizing Solution 2 is provided as a buffered solution containing <15% formaldehyde and <50% diethylene glycol and a proprietary permeabilizing agent.

DIRECT INTRACELLULAR IMMUNOFLUORESCENCE

Product/Amount
for Permeabilizing

BD FACS Permeabilizing Solution 2

Cat. No. 340973

500 µL/test of 1X Solution 2

Dilute 10X solution 1:10 in deionized (DI) water. Do not dilute in phosphate-buffered saline (PBS) or other buffers.


Method for Intracellular Staining

Refer to our website (www.bdfacs.com) or contact your BD representative for the BD intracellular staining procedure.

Abbreviated Intracellular Staining Procedure: Add 1 mL of 1X FACS™ Lysing Solution* (Cat. No. 349202) to 100 µL of activated heparinized whole blood. Incubate 10 minutes at room temperature. Centrifuge at 500 x g for 5 minutes; decant the supernatant. Add 0.5 mL of 1X FACS Permeabilizing Solution 2. Vortex and incubate for 10 minutes at room temperature. Wash by adding PBS containing 0.5% bovine serum albumin (BSA) and 0.1% NaN₃, and centrifuge for 5 minutes. Add appropriate volume of fluorescent-conjugated intracellular antibody. Vortex and incubate for 30 minutes at room temperature in the dark. Repeat wash step. Resuspend cells in 1% paraformaldehyde in PBS.

Representative Data

Performed on CMV-activated whole blood stained with FastImmune™ Anti-Hu-IFN-γ FITC/CD69 PE/CD4 PerCP[†]-Cy5.5[‡]. Laser excitation is at 488 nm.



Analyzed with a FACS brand flow cytometer

* US Patent Nos. 4,654,312; 4,902,613; and 5,098,849

† US Patent No. 4,876,190

‡ US Patent Nos. 5,268,486; 5,486,616; 5,569,587; 5,569,766; and 5,627,027

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

**BECTON
DICKINSON**

BD Biosciences
2350 Qume Drive
San Jose, CA 95131-1807
Ordering Information (800) 223-8226; Customer Support Center (800) 448-2347
www.bdfacs.com

HANDLING AND STORAGE

FACS Permeabilizing Solution 2 (10X) is stable for the period shown on the bottle label when stored as directed. Do not use this reagent if discoloration occurs or a precipitate forms. Store 1X solution at room temperature for up to 1 month.

WARRANTY

The products sold hereunder are warranted only to conform to the quantity and contents stated on the label at the time of delivery to the customer. There are no warranties, expressed or implied, which extend beyond the description on the label of the product. Becton Dickinson's sole liability is limited to either replacement of the products or refund of the purchase price. Becton Dickinson is not liable for property damage, personal injury, or economic loss caused by the product.

WARNING

Reagent contains diethylene glycol and formaldehyde. Formaldehyde is harmful by inhalation, in contact with skin, and if swallowed. It is irritating to eyes and skin. Exposure can cause cancer. Possible risks of irreversible effects. Can cause sensitization by skin contact. Keep locked up and out of the reach of children. Keep away from food, drink, and animal feedings. Wear suitable protective clothing and gloves. Even small amounts of diethylene glycol can be fatal. If swallowed, seek medical advice immediately and show this container or label. Dispose of according to federal, state, and local regulations.

REFERENCES

1. Asanuma H, Sharp M, Maecker HT, Maino VC, Arvin AM. Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus determined by intracellular detection of cytokine expression. *J Infect Dis*. In press.
2. Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus-specific CD4⁺ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. *Nat Med*. 1998;4:953-956.
3. Nomura LE, Walker JM, Maecker HT. Optimization of antigen-specific cytokine assays for CD4⁺ T cells. *Cytometry*. In press.
4. Suni MA, Picker LJ, Maino VC. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. *J Immunol Methods*. 1998;212:89-98.
5. Waldrop SL, Davis KA, Maino VC, Picker LJ. Normal human CD4⁺ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. *J Immunol*. 1998;161:5284-5295.
6. Waldrop SL, Pitcher CJ, Peterson DM, Maino VC, Picker LJ. Determination of antigen-specific memory/effector CD4⁺ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. *J Clin Invest*. 1997;99:1739-1750.
7. Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1-specific CD4⁺ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. *Nat Med*. 1999;5:518-525.
8. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. *Nat Med*. 1999;5:677-685.
9. Elson LH, Nutman TB, Metcalfe DD, Prussin C. Flow cytometric analysis for cytokine production identifies T helper 1, T helper 2, and T helper 0 cells within the human CD4⁺CD27⁻ lymphocyte subpopulation. *J Immunol*. 1995;154:4294-4301.
10. Picker LJ, Singh MK, Zdraveski Z, et al. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. *Blood*. 1995;86:1408-1419.